Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
SKRR to Commence Uranium Drill Program to Test Conductors at Clearwater West (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Lipocine Inc LPCN

Healthcare
Lipocine Inc. is a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery to develop differentiated products for Central Nervous System (CNS) disorders. Its clinical development candidates include: LPCN 1154, oral brexanolone, for treatment of postpartum depression, LPCN 2101 for epilepsy, LPCN 2203 for essential tremor... see more

Recent & Breaking News (NDAQ:LPCN)

Lipocine Set To Join Russell Microcap® Index

PR Newswire June 25, 2019

Lipocine Announces TLANDO(TM) NDA PDUFA Action Date of November 9, 2019

PR Newswire May 14, 2019

Lipocine Announces First Quarter 2019 Financial and Operational Results

PR Newswire May 8, 2019

Lipocine Seeks Injunction Against the Marketing of Clarus Therapeutics' JATENZO® for Testosterone Replacement Therapy

PR Newswire April 3, 2019

Lipocine Announces ABPM Labeling Study Results Consistent with Recently Approved Testosterone Replacement Therapy

PR Newswire March 27, 2019

Lipocine Late-Breaker Presentation at EASL Meeting to Detail LPCN 1144 MRI-PDFF Based Clinical Results on Reduction of Liver Fat and Key Serum Biomarkers

PR Newswire March 26, 2019

Lipocine to Participate at the ROTH Battle of the NASH Thrones Spring Investor Conference

PR Newswire March 21, 2019

Lipocine Announces Presentation Highlighting Therapeutic Potential of LPCN 1144 in NAFLD and NASH Selected for ENDO 2019

PR Newswire March 14, 2019

48 Stocks Moving In Wednesday's Mid-Day Session

Benzinga.com  March 13, 2019

Lipocine Surges On Positive 16-Week Liver Imaging Study For Its NASH Candidate

Benzinga.com  March 12, 2019

Lipocine's LPCN 1144 for NASH Demonstrates Substantial Fatty Liver Resolution and Meaningful Liver Fat Reduction in NAFLD Population

PR Newswire March 12, 2019

Lipocine to Participate at the 31st Annual ROTH Conference

PR Newswire March 11, 2019

Lipocine Announces Financial and Operational Results for the Year Ended December 31, 2018

PR Newswire March 6, 2019

Lipocine Inc. Announces FDA Clearance of IND to Commence Phase 2 Study of LPCN 1144 in Biopsy Confirmed NASH Subjects

PR Newswire February 14, 2019

Lipocine Files IND To Evaluate LPCN 1144 In Biopsy Confirmed NASH Subjects

PR Newswire January 24, 2019

Mid-Afternoon Market Update: Dow Turns Higher; Signet Jewelers Shares Plunge

Benzinga.com  January 17, 2019

34 Stocks Moving In Thursday's Mid-Day Session

Benzinga.com  January 17, 2019

Mid-Day Market Update: Insteel Industries Falls After Q1 Results; Lipocine Shares Jump

Benzinga.com  January 17, 2019

Mid-Morning Market Update: Markets Mostly Lower; Morgan Stanley Earnings Miss Estimates

Benzinga.com  January 17, 2019

22 Stocks Moving In Thursday's Pre-Market Session

Benzinga.com  January 17, 2019